-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WBBelaUKzBnMSoPZW5kzwUqsMzQLDMpE7w0+44MjHyQKPeuZ9Q6YuZBGtjSackSo oqdSnIZwVIo6t82x7RM5ug== 0001209191-08-067602.txt : 20081229 0001209191-08-067602.hdr.sgml : 20081225 20081229200633 ACCESSION NUMBER: 0001209191-08-067602 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081223 FILED AS OF DATE: 20081229 DATE AS OF CHANGE: 20081229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Covic Zeljko CENTRAL INDEX KEY: 0001392574 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09860 FILM NUMBER: 081273916 BUSINESS ADDRESS: BUSINESS PHONE: 201-930-3300 MAIL ADDRESS: STREET 1: 400 CHESTNUT RIDGE ROAD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BARR PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000010081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221927534 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 BUSINESS PHONE: 201-930-3300 MAIL ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 FORMER COMPANY: FORMER CONFORMED NAME: BARR LABORATORIES INC DATE OF NAME CHANGE: 19920703 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2008-12-23 1 0000010081 BARR PHARMACEUTICALS INC BRL 0001392574 Covic Zeljko 400 CHESTNUT RIDGE ROAD WOODCLIFF LAKE NJ 07677 0 1 0 0 COO of Pliva d.d. Stock Appreciation Rights 46.92 2008-12-23 4 D 0 30000 D 2008-11-11 2017-03-29 Common Stock 30000 0 D Stock Appreciation Rights 49.22 2008-12-23 4 D 0 37500 D 2008-11-11 2018-03-04 Common Stock 37500 0 D These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $587,400, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.92 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $648,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share. /s/ William T. McKee as Attorney-in-Fact for Zeljko Covic 2008-12-29 -----END PRIVACY-ENHANCED MESSAGE-----